Randomized Controlled Trial
Copyright ©The Author(s) 2022.
World J Gastroenterol. Nov 28, 2022; 28(44): 6294-6309
Published online Nov 28, 2022. doi: 10.3748/wjg.v28.i44.6294
Table 4 Overall Summary of treatment-emergent adverse events (safety set)
Fexuprazan 40 mg (n = 131)
Esomeprazole 40 mg (n = 131)
Total (n = 262)
n (%) [number of event]
Subjects with TEAEs22 (16.8) [34]25 (19.1) [34]47 (17.9) [68]
95%CI[10.4, 23.2][12.4, 25.8][13.3, 22.6]
P value10.629c
Subjects with ADRs9 (6.9) [13]7 (5.3) [11]16 (6.1) [24]
95%CI[2.5, 11.2][1.5, 9.2][3.2, 9.0]
P value10.606c
Subjects with serious TEAEs000
Subjects with serious ADRs000
Most frequently occurring (≥ 2%) TEAEs by system organ class and preferred term
System organ class preferred term
Gastrointestinal disorders
Diarrhoea4 (3.1) [4]2 (1.5) [2]6 (2.3) [6]
Nervous system disorders
Dizziness1 (0.8) [1]3 (2.3) [3]4 (1.5) [4]

  • Citation: Lee KN, Lee OY, Chun HJ, Kim JI, Kim SK, Lee SW, Park KS, Lee KL, Choi SC, Jang JY, Kim GH, Sung IK, Park MI, Kwon JG, Kim N, Kim JJ, Lee ST, Kim HS, Kim KB, Lee YC, Choi MG, Lee JS, Jung HY, Lee KJ, Kim JH, Chung H. Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis. World J Gastroenterol 2022; 28(44): 6294-6309
  • URL: https://www.wjgnet.com/1007-9327/full/v28/i44/6294.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v28.i44.6294